Scott Smith, Viatris CEO
Viatris licenses Idorsia’s PhIII heart and lupus drugs with $350M upfront
Viatris has inked a deal with Idorsia for a pair of late-stage drug candidates in a move that may reflect Viatris’ efforts to build its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
